Trevi Therapeutics Announces Positive Results from Phase 2b CORAL Trial of Haduvio for Chronic Cough in IPF Patients, Plans Phase 3 Initiation in 2026

Reuters
06-02
Trevi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Results from Phase 2b CORAL Trial of Haduvio for Chronic Cough in IPF Patients, Plans Phase 3 Initiation in 2026

Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis $(IPF.UK)$. The trial achieved its primary endpoint, showing statistically significant reductions in 24-hour cough frequency across all dose groups, including 108 mg BID and 54 mg BID (p <0.0001) and 27 mg BID (p<0.01), with a 43.3% placebo-adjusted change at the highest dose. Rapid reductions were noted as early as Week 2. Haduvio was generally well-tolerated, with discontinuation rates due to adverse events similar to those in the placebo group. Trevi plans to request an End-of-Phase 2 meeting with the FDA later in the year and intends to initiate a Phase 3 program in the first half of 2026. A conference call and webcast to discuss these results will be held today at 8:30 a.m. ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY00526) on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10